Observational studyBMC pulmonary medicine2025
Lung ultrasound alterations six months after COVID-19 pneumonia: a descriptive study.
Observational study in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosis.iScience · 2026Article
- Lung Ultrasound Abnormalities and LUS Score After COVID-19 Pneumonia: Determinants and Associations with Dyspnoea in a Prospective Cohort.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe primary aim of this study was to describe the prevalence and characteristics of lung ultrasound abnormalities six months after hospital discharge for COVID-19 pneumonia.
methodsThis prospective observational study included patients hospitalised with COVID-19 pneumonia between March 2020 and May 2022. Participants attended a follow-up visit between one and six months after discharge. A standardised 14-zone ultrasound protocol was applied in all cases. Clinical variables and symptoms, including dyspnoea graded using the modified Medical Research Council (mMRC) scale, were recorded.
resultsThe median time from discharge to follow-up assessment was 75 days. Lung involvement on ultrasound was frequent, observed in 79.3%. The most common findings were pleural line irregularities with B-lines (75.9%) and subpleural consolidations (35.6%). A B-line count ≥ 3 per segment was noted in 38.3%. Abnormalities were more common in the basal lung regions. Dyspnoea was the main respiratory symptom, reported by 67% with varying degrees on the mMRC scale.
conclusionsCOVID-19 pneumonia remains a significant public health concern, particularly among high-risk groups susceptible to severe disease and post-COVID sequelae. Efficient screening methods are needed for evaluating potential sequelae. The technical features of lung ultrasound-its accessibility, safety, reproducibility, and ability to detect pulmonary abnormalities during post-COVID follow-up-may render it a valuable tool for patient monitoring. In our series, lung ultrasound findings (pleural line irregularities, B-lines, and subpleural consolidations) were frequent. However, further studies correlating sonographic findings with associated factors and persistent symptoms are required to confirm and validate its role in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.